Krishna Ella

Krishna Ella, managing director of Bharat Biotech. (Bharatbiotech.com photo)

BENGALURU — An Indian biotech company’s “breakthrough” claim that it has developed two “candidate vaccines” against the Zika virus — while being hailed as a ‘made in India’ product — has alarmed some virologists.

Krishna Ella, managing director of the Hyderabad-based Bharat Biotech, announced last week that his company is probably the first in the world to file a “global patent” for its vaccines against the virus that is suspected to cause birth defects and neurological problems, and is terrorizing Brazil and other countries in South America. The company said it started work on the vaccines a year ago using the “live” Zika virus. But despite repeated requests from IANS, neither Ella nor the company’s spokesperson revealed from where or when the company got this virus.

“It is a serious question,” said Kalyan Banerjee, a renowned virologist and former director of the National Institute of Virology in Pune, a premier laboratory under the Indian Council of Medical Research.

“Normally one should not import any exotic virus into the country under any pretext,” Banerjee told IANS in an email. “Only the government of India’s biotechnology board or a similar body is authorized to give permission to import after ascertaining all aspects of the virus.”

“It is amazing how the said laboratory obtained the live virus, particularly when there is no record of isolation of the Zika virus from the Indian subcontinent,” Banerjee said.

The Zika virus is spread by the Aedes Aegypti species of mosquitoes that are abundant in India.

“Regarding the company getting the virus and making a vaccine, it needs to be carefully investigated,” Banerjee said, pointing out that “loopholes in the importation of pathogenic agents may lead to a national disaster.”

He said strict vigilance was one main reason why the yellow fever virus, which is also spread by Aedes mosquitoes and causes a fatal disease, never came to India.

Durga Rao, another leading virologist at the Indian Institute of Science here, agrees. One can import a virus from any source with approval from ICMR or the department of biotechnology, “but unauthorized introduction of a virus which is not reported yet in India by anyone could be a serious regulatory problem, as it can get into the environment easily under our unsupervised facilities,” Rao said in an email.

But inquiries reveal that the vaccine maker failed to follow the standard procedure for importing the live Zika virus whose potential threat to newborns forced the World Health Organization Feb. 1 to declare a global emergency.

“We did not import the virus, and Bharat (Biotech) got it themselves,” ICMR director general Soumya Swaminathan told IANS in an email response to a query regarding if the company sought its permission to import.

“There are safety concerns with the Zika virus vaccine, so all the steps in the regulatory approval need to be followed,” she said.

Asked if the DBT gave permission, its secretary K. Vijayraghavan, instead of an emphatic yes or no, said that the question “is best addressed to the industry concerned.” In an email, he said the DBT is committed to working with ICMR and the health ministry to ensure preparedness.

Apart from its reluctance to reveal the source of the virus used to develop the vaccines, the company has declined to give details about the global patent it claims to have filed in July 2015.

A search of the Indian Patent Office Web site for Bharat Biotech’s patent applications, or the company’s own Web site, does not show any specific filing for the Zika virus. One patent expert told IANS that “it is possible that the patent office hasn’t yet published this patent application.”

Some scientists are impressed and at the same time intrigued by the Indian company’s foresight in trying to develop a vaccine for a disease that was not yet there.

According to a report in the journal Science, “less than a year ago, Zika seemed too trivial for anyone to bother developing countermeasures,” and Brazil reported its first case (microcephaly) of the Zika virus only in May 2015.

“But Bharat Biotech says it started work on the vaccine as early as in 2014 and filed for patents for two vaccines in July 2015 itself,” said one medical researcher who did not want to be named. “This defies credibility.”

But Bharat Biotech has dismissed this argument saying the company was already developing vaccines for chikungunya and dengue, and it was natural to work also on a vaccine for the Zika virus, which is spread by the same species of mosquito.

Although the Indian company has an early start in vaccine development, bringing the vaccine to the market will be years away, experts say. There is no monkey model yet to enable comparisons of candidate vaccines, and human trials have to be done in endemic countries like Brazil, not in India.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.